论文部分内容阅读
目的:观察洛伐他汀对非酒精性脂肪性肝炎治疗的疗效,探讨洛伐他汀降血脂改善肝脏脂肪变性与炎性程度的作用。方法:90例患者随机分为洛伐他汀组和对照组两组,每组45例,洛伐他汀组在常规保肝治疗基础上采用洛伐他汀治疗,对照组只进行常规保肝治疗,分别观察疗效。结果:洛伐他汀组与对照组疗程结束后,血脂水平及肝功能情况均有显著改变(P<0.05);洛伐他汀组治疗后显效36例,有效7例,无效2例;对照组显效28例,有效10例,无效7例;洛伐他汀组降血脂改善肝功能的效果也明显好于对照组,两组疗效差异有统计学意义(P<0.05)。结论:洛伐他汀应用于治疗脂肪肝效果明显,不良反应小。
Objective: To observe the effect of lovastatin on the treatment of non-alcoholic steatohepatitis, and to explore the effect of lovastatin on reducing hepatic steatosis and inflammatory degree. Methods: Ninety patients were randomly divided into lovastatin group and control group, with 45 cases in each. Lovastatin group was treated with lovastatin on the basis of conventional hepatoprotective therapy, while the control group was treated only with conventional hepatobiliary therapy Observe the effect. Results: In the lovastatin group and the control group, the levels of blood lipid and liver function were significantly changed after treatment (P <0.05); in the lovastatin group, 36 cases were markedly effective, 7 cases were effective and 2 cases were ineffective; the control group was markedly effective 28 cases, effective in 10 cases and ineffective in 7 cases. The effect of lowering blood fat and improving liver function in lovastatin group was also significantly better than that in control group. The difference between the two groups was statistically significant (P <0.05). Conclusion: Lovastatin is effective in treating fatty liver and its adverse reaction is small.